Joshua Brumm
2022 - Dyne Therapeutics
In 2022, Joshua Brumm earned a total compensation of $4.3M as President and Chief Executive Officer at Dyne Therapeutics, a 6% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $335,500 |
---|---|
Option Awards | $1,661,236 |
Salary | $610,000 |
Stock Awards | $1,709,371 |
Other | $996 |
Total | $4,317,103 |
Brumm received $1.7M in stock awards, accounting for 40% of the total pay in 2022.
Brumm also received $335.5K in non-equity incentive plan, $1.7M in option awards, $610K in salary and $996 in other compensation.
Rankings
In 2022, Joshua Brumm's compensation ranked 781st out of 5,756 executives tracked by ExecPay. In other words, Brumm earned more than 86.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 781 | 86th |
Manufacturing | 353 | 89th |
Chemicals And Allied Products | 117 | 92nd |
Drugs | 104 | 92nd |
Pharmaceutical Preparations | 76 | 92nd |
Brumm's colleagues
We found three more compensation records of executives who worked with Joshua Brumm at Dyne Therapeutics in 2022.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020